MPM Bioimpact LLC Takes Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

MPM Bioimpact LLC acquired a new stake in Vera Therapeutics, Inc. (NASDAQ:VERA) in the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 257,788 shares of the company’s stock, valued at approximately $10,902,000.

Other institutional investors have also added to or reduced their stakes in the company. Avoro Capital Advisors LLC raised its position in Vera Therapeutics by 30.2% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company’s stock worth $237,247,000 after acquiring an additional 1,300,410 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Vera Therapeutics by 11.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,377,049 shares of the company’s stock worth $185,107,000 after acquiring an additional 437,940 shares during the period. FMR LLC grew its stake in Vera Therapeutics by 9.6% during the fourth quarter. FMR LLC now owns 3,053,126 shares of the company’s stock worth $129,117,000 after buying an additional 267,842 shares in the last quarter. Vanguard Group Inc. raised its position in Vera Therapeutics by 14.3% during the fourth quarter. Vanguard Group Inc. now owns 2,949,564 shares of the company’s stock valued at $124,737,000 after purchasing an additional 369,387 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP grew its position in Vera Therapeutics by 31.0% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 1,437,339 shares of the company’s stock valued at $60,785,000 after acquiring an additional 340,488 shares during the last quarter. 99.21% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently commented on VERA. The Goldman Sachs Group initiated coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They set a “buy” rating and a $58.00 price target on the stock. Wedbush decreased their price target on shares of Vera Therapeutics from $34.00 to $26.00 and set a “neutral” rating for the company in a research note on Wednesday, May 7th. Guggenheim raised their price objective on Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. JPMorgan Chase & Co. dropped their price target on Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a report on Tuesday, March 4th. Finally, Wolfe Research began coverage on shares of Vera Therapeutics in a report on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $63.33.

Vera Therapeutics Trading Down 4.0%

VERA opened at $21.58 on Wednesday. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. The stock has a 50-day moving average of $23.92 and a 200 day moving average of $34.43. Vera Therapeutics, Inc. has a 12 month low of $18.53 and a 12 month high of $51.61. The firm has a market cap of $1.38 billion, a P/E ratio of -8.27 and a beta of 1.28.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same period in the previous year, the company posted ($0.56) EPS. As a group, research analysts forecast that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.